While NLRP3 inflammasome activation is a promising therapeutic target for the treatment of atherosclerosis (Figure 3), and most of its beneficial effects are seen in experimental studies, developing other NLRP3-modifying agents is necessary to address the limitations of current agents. Here, NLRP3 is linked to atherosclerosis.